Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 29/10/2020
SIETES contiene 93137 citas

 
Ref. ID 103706
 
Tweet
Schachar RA, Schachar IH. A SARS-CoV-2 mRNA Vaccine — Preliminary Report
The New England Journal of Medicine (N Engl J Med)
19 de agosto 2020
página(s) 1

The positive antibody response to the messenger RNA (mRNA) vaccine described by Jackson et al. (published online on July 14 at NEJM.org)1 is a hopeful step toward controlling the Covid-19 pandemic.

However, this vaccine and other DNA and RNA vaccines against SARS-CoV-2 continuously stimulate cellular production of the target antigen.

A mechanism is required to be able to stop the antigen production after a period of time to avoid the possibility of eventual desensitization, as is seen with allergen immunotherapy.2-5 Without such a mechanism, a sustained lack of response may make SARS-CoV-2 infection a lot worse in the long run.

It will be important to evaluate this potential before declaring that any DNA or RNA vaccine is safe and efficacious.